GB3226 / Galecto, Bridge Medicines - LARVOL DELTA

Galecto Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire) - "...'During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML'....'We continued preclinical studies to support our planned IND submission, which remains on track for Q1 2026. To date, preclinical data have shown significant improvement in efficacy compared to current FLT3 and menin inhibitors, with activity across a broad spectrum of patient genotypes'."

IND • Preclinical • Acute Myelogenous Leukemia

Galecto Reports Full-Year 2024 Financial Results (GlobeNewswire) - "Acquired global rights to Bridge Medicines’ BRM-1420 program, now GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML). GB3226 is a potent and selective inhibitor designed to disrupt key oncogenic pathway signaling. Preclinical data showed GB3226’s superior efficacy to both FLT3 and menin inhibitors in animal models, as well as additive or synergistic activity in combination with standard-of-care treatments....GB3226 on track for IND submission in Q1 2026."

IND • Preclinical • Acute Myelogenous Leukemia

Galecto Reports Third Quarter 2024 Financial Results (GlobeNewswire) - "Galecto plans to submit an investigational new drug application (IND) for BRM-1420 in the US in late 2025 or early 2026 and initiate clinical studies in patients with AML thereafter."

IND • New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines (GlobeNewswire) - "Galecto, Inc...announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive results in non-small cell lung cancer (NSCLC) and decompensated cirrhosis clinical studies. Galecto further announced that it has bolstered its pipeline with the acquisition of the global rights to BRM-1420, a novel, first-in-class asset developed by Bridge Medicines, a company co-founded by Takeda...As consideration for the acquisition of the global rights of BRM-1420, Galecto issued 62,594 shares of common stock to Bridge Medicines...As part of the strategic alternative review process, Galecto has determined not to further advance GB2064, its LOXL-2 inhibitor candidate, at this time....Galecto plans to file an IND for BRM-1420 in the US in late 2025 or early 2026 and initiate clinical studies in patients with AML thereafter."

Commercial • Discontinued • IND • Pipeline update • Acute Myelogenous Leukemia • Myelofibrosis • Non Small Cell Lung Cancer